Paul Maguire Enterprise Ireland

  • Published on
    14-Jan-2016

  • View
    42

  • Download
    0

Embed Size (px)

DESCRIPTION

Biotechnology Commercialisation in Ireland - Looking to the Future. Paul Maguire Enterprise Ireland. Federal Lab Consortium (FLC) / Mid-Atlantic Region (MAR) Regional Meeting - September 20 th , 2006 Cumberland, Maryland. ENTERPRISE IRELANDS KEY ROLE. - PowerPoint PPT Presentation

Transcript

  • Paul Maguire Enterprise IrelandBiotechnology Commercialisation in Ireland- Looking to the FutureFederal Lab Consortium (FLC) / Mid-Atlantic Region (MAR)Regional Meeting - September 20th, 2006Cumberland, Maryland

  • ENTERPRISE IRELANDS KEY ROLE

    To accelerate the development of world-class Irish companies to achieve strong positions in global markets resulting in increased national and regional prosperity

    12 Offices in Ireland34 Offices Overseas incl. 5 in the USA

  • EIs US Office NetworkSouth AmericaCanadaphysical office location4 Employees16 Employees2 Employees3 Employees1 Employees

  • Over eight years Ireland has changed dramatically. With changing times and a great deal of success new challenges and new opportunities have arisen.

    Ireland today has: The lowest level of unemployment in the EU The second lowest national debt The second highest minimum wage The highest investment in the EU on infrastructure The fastest growth of all OECD countries in spending per capita on health The most generous tax and welfare system in the world for single income families on the average industrial wage. Introduction to the Third Government Progress Report, July 2005

  • Irelands GDP per CapitaOECD

    Chart1

    6408

    9215

    10846

    12255

    13894

    15102

    17016

    18434

    18439

    21783

    22406

    25568

    25810

    25917

    26019

    26495

    26954

    27209

    27217

    27716

    27948

    28068

    28399

    28872

    29009

    29231

    30303

    30455

    32646

    35482

    36121

    49150

    Sheet1

    19952000200520102015

    12.24.34.23.62.7

    Sheet1

    0

    0

    0

    0

    0

    Forecast Unemployment

    Sheet2

    Sheet3

  • R&D Expenditure1.2Gross domestic expenditure on R&DAs a percentage of GDP, 20042.7

    Chart2

    0.39

    0.53

    0.56

    0.62

    0.66

    0.73

    0.7773048178

    0.78

    0.88

    0.93

    1.05

    1.16

    1.16

    1.16838

    1.21

    1.28

    1.440582

    1.69

    1.75

    1.78

    1.84

    1.88

    1.89

    1.91

    1.93

    2.16

    2.255

    2.256

    2.49

    2.57

    2.62

    2.63

    2.68

    2.97

    3.15

    3.48

    3.98

    Chart

    OECD Factbook 2006 - ISBN 92-64-03561-3 - OECD 2006

    Science and technology - research and development (R&D) - expenditure on R&DGross domestic expenditure on R&D (GERD)

    As a percentage of GDP, 2004 or latest available year

    Gross domestic expenditure on R&DMexico0.39

    As a percentage of GDP, 2004 or latest available yearSlovak Republic0.53

    Poland0.56

    Greece0.62

    Turkey0.66

    South Africa0.73

    India0.78

    Portugal0.78

    Hungary0.88

    Brazil0.93

    Spain1.05

    Italy1.16

    New Zealand1.16

    Russian Federation1.17

    Ireland1.21

    Czech Republic1.28

    China1.44

    Australia1.69

    Norway1.75

    Luxembourg1.78

    Netherlands1.84

    United Kingdom1.88

    Belgium1.89

    EU151.91

    Canada1.93

    France2.16

    Austria2.26

    OECD total2.26

    Germany2.49

    Switzerland2.57

    Denmark2.62

    Korea2.63

    United States2.68

    Iceland2.97

    Japan3.15

    Finland3.48

    Sweden3.98

    &C&Z&F

    Chart

    0

    0

    0

    0

    0

    0

    0

    0

    0

    0

    0

    0

    0

    0

    0

    0

    0

    0

    0

    0

    0

    0

    0

    0

    0

    0

    0

    0

    0

    0

    0

    0

    0

    0

    0

    0

    0

  • Life Science investment 2000-04 Investment in R&D Base:

    1.3 billion invested in R&D- 645m SFI; 605m HEA.

  • National Centres National Centre for BiomedicalEngineering Science NUIG The Bioscience Research Institute University College Cork Conway Institute UCDThe Institute of Immunology, located in the Bioscience Building, NUI Maynooth The Trinity Centre for BioEngineering (TCBE)

  • Life-science Companies17% Diagnostics

    20% Drug Discovery and Development

    17% Pharmaceuticals and Chemicals

    20% Medical Devices

    26% Services and Support Approx. 70 Indigenous CompaniesAlso- Food industry investing heavily in R&D for functional foods

  • BELFAST

    DUBLIN

    CORK

    GALWAY

    Clusters of Irish Biotech Companies

    Sheet1

    No. Cos5

    No. Indig. Cos.3

    No. of Staff226

    No. of R&D Staff14

    Sheet2

    Sheet3

    Sheet1

    No. Cos3

    No. Indig. Cos.3

    No. of Staff54

    No. of R&D Staff16

    No. Cos8

    No. Indig. Cos.4

    No. of Staff1050

    No. of R&D Staff40

    No. Cos

    8

    No. Indig. Cos.

    4

    No. of Staff

    1,050

    No. of R&D Staff

    40

    Sheet2

    Sheet3

    Sheet1

    No. Cos16

    No. Indig. Cos.12

    No. of Staff829

    No. of R&D Staff71

    No. Cos8

    No. Indig. Cos.4

    No. of Staff1050

    No. of R&D Staff40

    No. Cos

    8

    No. Indig. Cos.

    4

    No. of Staff

    1,050

    No. of R&D Staff

    40

    Sheet2

    Sheet3

    Sheet1

    No. Cos14

    No. Indig. Cos.14

    No. of Staff538

    No. of R&D Staff174

    No. Cos8

    No. Indig. Cos.4

    No. of Staff1050

    No. of R&D Staff40

    No. Cos

    8

    No. Indig. Cos.

    4

    No. of Staff

    1,050

    No. of R&D Staff

    40

    Sheet2

    Sheet3

  • Government StrategyHigh levels of investment in research and innovation are essential in order to become a competitive and dynamic knowledge-based economy.http://www.entemp.ie/publications/science/2006/sciencestrategy.pdf

  • Over the life of this Strategy we aim to see a doubling of postgraduate researchers, with significant numbers of these going on to take up employment in the enterprise sector. We also aim to ensure more effective commercialisation of the ideas and know-how being generated in our universities and public research institutions, and to forge new partnerships between these institutions and enterprise.Bertie Ahern T.D.TaoiseachPrime Minister of Ireland

  • Focus of Strategy

    World Class Research Capturing, Protecting and Commercialising Ideas and Know-howResearch and Development for Enterprise, Innovation and Growth Science Education and Society Research in the Public SectorAll-Island and International STI Implementation

    The creation, exploitation and commercialisation of research are critical if Ireland is to overcome competitive threats and sustain its economic momentum.

  • Technology TransferTransfer of knowledge and technology from higher education institutes into the marketplace is recognised as being of crucial importance in the establishment of a strong research environment and a knowledge-based economy.

  • EI-Bio Supports for Biotech.EI Bio is building the biotechnology sector through the strategic commercialisation of research in Ireland.2 approaches to commercializing research:

    Funding mechanisms to provide financial support for the development of these technologies.- support all levels of technology development from proof of concept to commercialisation and beyond.

    Commercialization support to help the researcher develop the technology within a commercial context.- On-campus personnel to support all aspects of IP identification, protection and exploitation.

  • Intellectual PropertyNational Code of Practice for Managing Intellectual Property from Publicly Funded Research- 2004Research Institute owns the IP

    National Code of Practice for Managing Intellectual Property from Public-Private Collaborative Research- 2005Ownership determined by intellectual and financial input and ability to exploit.

  • Institutional Technology TransferStrengthening the Technology Transfer Function (The 3rd Stream)Technology Transfer is the link between Research and the Market- Increased funding and support30m over 5 years.

    Integral part of institutional strategy.Clear realistic goals based on track record.Based on National Codes of Practice.Offices resourced appropriately.Central support provided by EI.

  • Technology Transfer will only occur when university and industry representatives work together for mutual gain.

    - Industry-led networks (2m)Industry-informed research projects carried out by academia.

    - Competence Centres (10-20m)Long term research programmes in academic centres managed by industry and academia.Industry- Academia Linkages

  • Strategic EmphasisIncreased emphasis on National Approach to capability building.

    Overall innovation performance of the economy is not dependant on how specific institutions perform, but rather on how they interact with each other as elements of a collective system of knowledge creation and use. (OECD 1994)

  • EI Programmes

  • TechnologyTransferInfrastructureBasic ResearchState AidInvestment

  • Questions.?

  • Paul MaguireSVP Market Development Enterprise IrelandWashington DCpaul.maguire@enterprise-ireland.com

    On behalf of

    Paul RobenDirector, Biotechnology CommercialisationEnterprise Irelandpaul.roben@enterprise-ireland.com

    Thank You!

    Another point of relevance is where the companies are located. This slide shows that the majority (43 of the 59) are clustered around the major cities. Dublin has the single largest concentration of companies . Belfast has the largest concentration of R&D staff, significantly more than the other three cities combined, and Cork has the largest number